Hints and tips:
...We cross-check our PT with a 2024E P/E multiple discounted to present value; our PT would imply a 15x P/E multiple vs 23.0x developed Sx pharma 12m forward P/E average....
...Mr Rothschild left the company’s board last October after raising concerns about loans made by PT Bumi Resources, one of Bumi’s Indonesian affiliates....
...Analysts expect to see more client-side solutions adoption in the year ahead....
International Edition